Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer healthcare platform said it couldn’t guarantee it would be able to continue selling its knockoff versions of weight-loss drugs Ozempic and Wegovy.
Despite reporting…